Slide 1

Michael Bartos (bartosm@unaids.org) UZ-UCSF Annual Research Day 17 April 2015 Fast-track to ending AIDS in Zimbabwe: 90.90.90 opportunities

Slide 2

1. WHY THE 90.90.90 TARGETS? 2. TESTING SHIFTING TO YIELDS 3. TREATMENT ACHEIVEMENTS AND CHALLENGES 4. SUSTAINING VIRAL SUPPRESSION 5. FINANCING THE RESPONSE 6. CONCLUSION Outline

Slide 3

Slide 4

New HIV infections in low- and middle-income countries, 20102030, with achievement of ambitious Fast-Track Targets, compared to maintaining 2013 coverage

Slide 5

AIDS-related deaths in low- and middle-income countries, 20102030, with achievement of ambitious Fast-Track Targets, compared to maintaining 2013 coverage

Slide 6

Ending the AIDS epidemic: A working definition Ending the AIDS epidemic as a public health threat by 2030 is provisionally defined as reducing new HIV infections, stigma and discrimination experienced by people living with HIV and key populations, and AIDS-related deaths by 90% from 2010 levels, such that AIDS no longer represents a major threat to any population or country

Slide 7

Global targets for ending the AIDS epidemic

Slide 8

Ambitious but achievable treatment target

Slide 9

By 2020 90% of all people living with HIV will know their HIV status 90% of all people diagnosed with HIV will receive sustained antiretroviral therapy. 90% of all people receiving antiretroviral therapy will have durable suppression.

Slide 10

What would ending AIDS targets look like for Zimbabwe 2030 results ? New infections down 13% year on year 100,000 in 2010 currently (2013) 69,000 to 63,000 in 2015 (current projection) to 25,000 in 2020 and 10,000 in 2030 AIDS deaths down from 90,000 in 2010 currently (2013) 64,000 to 27,000 in 2015 (current projection) to 9,000 in 2030

Slide 11

1. WHY THE 90.90.90 TARGETS? 2. TESTING SHIFTING TO YIELDS 3. TREATMENT ACHEIVEMENTS AND CHALLENGES 4. SUSTAINING VIRAL SUPPRESSION 5. FINANCING THE RESPONSE 6. CONCLUSION Outline

Slide 12

Testing: volume or yield? 13m total population 40% under 15 (5.2m) Over 15 infected or at risk (7.8m) Already tested + about 1m Pool of potential unknowns around 6m Current test volume 2.5m, 2018 target 3m annually

Slide 13

Testing results from the 2013 MICS % of sexually active young people tested in past 12 months All ever tested Tested past 12 mths

Slide 14

Korenromp and Stover, Democratizing Testing, UNAIDS April 2015

Slide 15

HIVST market intervention Country # Tests Phase 1 # Tests Phase 2 Malawi172,754420,466 South Africa036,000 Zambia200,478404,522 Zimbabwe359,1901,069,810 Total732,4221,930,798

Slide 16

1. WHY THE 90.90.90 TARGETS? 2. TESTING SHIFTING TO YIELDS 3. TREATMENT ACHEIVEMENTS AND CHALLENGES 4. SUSTAINING VIRAL SUPPRESSION 5. FINANCING THE RESPONSE 6. CONCLUSION Outline

Slide 17

Slide 18

Ending AIDS 81% coverage target Zimbabwe ART coverage targets 2014-2016

Slide 19

1. WHY THE 90.90.90 TARGETS? 2. TESTING SHIFTING TO YIELDS 3. TREATMENT ACHEIVEMENTS AND CHALLENGES 4. SUSTAINING VIRAL SUPPRESSION 5. FINANCING THE RESPONSE 6. CONCLUSION Outline

Slide 20

Retention of Patients Initiating ART During 2007-2009, Zimbabwe Good retention in care observed in a retrospective cohort study in a nationally representative sample of patients initiating ART between 2007 and 2009 69% of patients were continuing ART treatment at 24 months, whereas 7% had died and 24% were lost to follow-up (MOHCW, 2012)

Slide 21

90% of those on ART virally suppressed: trade offs? Initiation vs. retention Routine viral load vs. on demand Maximally effective regimen vs. maximally forgiving regimen

Slide 22

Community ART refill groups Model self-selecting patient groups (7-14) one representative picks up ARVs for the group on quarterly basis group contribute money for transport/ lunch/in kind support (eg work their fields) Results: 9 months pilot evaluation (n=207) 100% retention, 99% virally suppressed Time saving: normally 45mins waiting, 50 mins with staff (nurse, counsellor, pharmacist); ART refill groups: 30 mins to serve 8 patients saving >10 person/hours per day in a busy 3 person clinic Cost savings to patients from $14 per month to $48 (more remote areas) Secondary benefits in increased resilience, reduced stigma, more participation in health governance.

Slide 23

1. WHY THE 90.90.90 TARGETS? 2. TESTING SHIFTING TO YIELDS 3. TREATMENT ACHEIVEMENTS AND CHALLENGES 4. SUSTAINING VIRAL SUPPRESSION 5. FINANCING THE RESPONSE 6. CONCLUSION Outline

Slide 24

PEPFAR: The United States Presidents Emergency Plan for AIDS Relief Sources: UNAIDS estimates, UNAIDSKaiser Family Foundation reports on financing the response to HIV in low- and middle-income countries, GARPR 2014, philanthropic resource tracking reports from Funders Concerned About AIDS, reports from the Global Fund and UNITAID. Building on past achievements: funds invested in AIDS programmes in low- and middle-income countries, 19862013

Slide 25

Potential room for expansion: per capita health assistance, selected countries Zimbabwe

Slide 26

Public resource Availability for AIDS in Zimbabwe, 2009-2016, US $ million

Slide 27

Resource needs for AIDS 2015-2025 in two different scenarios: current coverage and enhanced, more efficient coverage

Slide 28

Slide 29

Additional impact: infections averted

Slide 30

Additional impact: deaths averted

Slide 31

CONCLUSION 1.Sustainability will require much more community delivery 2.Patient-driven diagnostics and regimen switching 3.Testing shift from undifferentiated to targeted yield 4.No one turned away 5.More money will be needed (also to turn off the tap)